Table 2

Sleep apnoea severity, sleep quality, nasal airflow resistance, and diary record details during treatment with fluticasone and placebo

VariableTotal population (n = 23)Apnoeic snorers (group A) (n = 13)Non-apnoeic snorers (group S) (n = 10)
FPFPFP
Data are shown as median (quartile range).
AHI = apnoea/hypopnoea index; NAR = nasal airway resistance; TST = total sleep time; TOT = total sleep period time; REM = rapid eye movement sleep; Sao2 = percentage arterial oxygen saturation; F = fluticasone; P = placebo.
*p<0.05; **p<0.01.
AHI11.9 (22.6)*20 (26.3)23.3 (21.3)*30.3 (31.9)2.7 (2.15)5.0 (6.3)
NAR2.74 (1.21)**3.27 (1.38)2.88 (1.49)**3.17 (1.6)2.71 (0.76)3.47 (1.19)
TST394 (47.5)382 (37)389.5 (53.8)380.5 (30.8)397.5 (46.3)391.8 (59.5)
TST/TOT (%)93.6 (8.3)92.1 (7.4)91.7 (10.2)91.7 (6.1)95.3 (8.5)*93.5 (12.7)
Stage 1 (%)9.4 (10.1)10.0 (10.1)12.1 (9.8)11.7 (4.4)8.3 (5.5)7.9 (2.4)
Stage 2 (%)53.7 (18.9)*63.5 (19.8)59.8 (15.8)67.3 (14.7)47.4 (10.5)58.1 (21.5)
Stage 3 (%)9.0 (8.6)6.4 (8.7)7.4 (11.0)5.1(8.7)9.8 (8.0)8.4 (4.8)
Stage 4 (%)7.8 (17.3)4.6 (10.6)0 (5.9)(5.5) 12.22.0 (16.8)5.6 (13.3)
Stage REM (%)13.4 (10.4)12.5 (5.3)10.9 (8.0)10.5 (4.2)17.1 (11.2)14.8 (5.7)
Mean Sao294.6 (2.37)94.6 (2.73)94.4 (2.0)94.3 (2.41)95.9 (2.5)95.3 (3.1)
Minimum Sao282 (10)83 (14)78 (11.5)78 (14)85.5 (6.5)86 (15.5)
Subjective nasal congestion2.2 (0.8)*2.3 (0.6)2.4 (1.0)2.6 (0.9)2.0 (1.1)**2.3 (0.3)
Daytime alertness2.2 (0.7)*2.3 (0.9)2.1 (0.7)2.2 (0.7)2.3 (1.1)*2.5 (0.5)
Subjective sleep quality1.8 (1.0)2.0 (0.9)1.7 (1.0)1.8 (1.1)1.9 (1.1)2.2 (1.1)
Partner-reported snoring2.9 (1.4)2.9 (1.5)3.3 (1.4)3.3 (1.8)2.5 (0.9)2.7 (0.6)